The Efficacy, Onset of Effect, and Safety of Alfuzosin Once Daily in the Treatment of Lower Urinary Tract Symptoms of Benign Prostatic Hyperplasia: A Randomized, Placebo-Controlled Trial Using an Acute International Prostate Score

Lead Sponsor

Sanofi

Age

50 - No limit years

Sex

MALE

Healthy Volunteers

No

•\- Men aged greater than or equal to 50 years with a history of lower urinary tract symptoms (LUTS) related to BPH for greater than or equal to 6 months, an International Prostate Symptom Score (I-PSS) (0 to 35 points scale) of at least 13 points, a maximum urinary flow rate (Qmax) between 5 and 12 mL/sec (with a voided volume of greater than or equal to 150 mL), a residual urine volume of less than or equal to 350 mL, and a bothersomeness score (0 to 6 points scale) of at least 3 points. All patients will undergo prostate size assessment by transrectal ultrasonography (TRUS) if not done within past 12 months.

•\- Include, but are not limited to: concomitant lower urinary tract disease; previous prostatic surgery; history of postural hypotension or syncope; concomitant use of medications that may alter the voiding pattern; and clinically relevant biochemical abnormalities. Patients with a serum prostate-specific antigen (PSA) \>10 ng/mL will be excluded, and those with an elevated serum PSA between 4 and 10 ng/mL must have prostate cancer excluded to the satisfaction of the investigator.
•The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Related studies

NCT07650968 · Acute Urinary Retention, Benign Prostatic Hyperplasia

NCT07643220 · Moderate-to-severe Benign Prostatic Hyperplasia (BPH)

NCT07629479 · Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms, and more

NCT05574244 · Benign Prostatic Hyperplasia

NCT06668142 · Benign Prostatic Hyperplasia